Consolidative Ipilimumab and Nivolumab With Thoracic Radiotherapy After Platinum Based Chemotherapy for Patients With Extensive-Stage Small Cell Lung Cancer

Trial Profile

Consolidative Ipilimumab and Nivolumab With Thoracic Radiotherapy After Platinum Based Chemotherapy for Patients With Extensive-Stage Small Cell Lung Cancer

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 May 2018

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 May 2018 Planned End Date changed from 1 Apr 2021 to 1 Apr 2022.
    • 10 May 2018 Status changed from recruiting to active, no longer recruiting.
    • 14 Feb 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top